Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports a material event occurring on September 11, 2025. The filing details the closing of an underwritten public offering by the Company's subsidiary, Lucid Diagnostics Inc.
Key Financial Metrics
- Shares Sold: 28,750,000 shares of Lucid Diagnostics common stock.
- Offering Price: $1.00 per share.
- Underwriters' Option: The full option to purchase an additional 3,750,000 shares was exercised.
- Net Proceeds: Approximately $26.9 million (after deducting underwriting discounts and estimated expenses).
- Use of Proceeds: Working capital and general corporate purposes for Lucid Diagnostics.
Material Changes
The primary material change is the successful completion of the equity offering by the subsidiary. This transaction increases the capital base of Lucid Diagnostics and results in the issuance of new shares to the public. The filing does not provide comparative financial data for Pavmed Inc. or Lucid Diagnostics for prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes. The offering was conducted pursuant to an existing shelf registration statement (Form S-3, No. 333-268560).
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard execution of the offering. Further details regarding the offering agreements are incorporated by reference from Lucid Diagnostics' own Form 8-K filings dated September 10 and 11, 2025.
Investor Verification Checklist
- Verify the exact amount of underwriting discounts and expenses deducted to reach the $26.9 million net proceeds figure.
- Review the prospectus supplement dated September 10, 2025, for specific terms of the underwriting agreement.
- Confirm the post-offering ownership structure of Lucid Diagnostics and any dilution impact on existing shareholders.
- Check subsequent filings for the actual deployment of the $26.9 million in working capital.